Antigen–IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα
These findings nominate a lead B-cell maturation antigen (BCMA)-IL-2 CAR-E candidate with strong translational potential for clinical development and establish IL-2Rβγ as a key driver of CAR-E activity. The results also identify IL-2Rα as dispensable and provide a mechanistic framework for designing safer, IL-2Rα-sparing CAR-Es.
Authors
- Harris H. Allen (ORCID: https://orcid.org/0009-0001-4800-4700)
- Jessika Baral
- Elodie Marcandalli
- A Wolff (ORCID: https://orcid.org/0009-0004-4209-4129)
- Hadi T. Nia (ORCID: https://orcid.org/0000-0003-1970-9901)
- Dayna L. Mercadante (ORCID: https://orcid.org/0000-0001-7141-9835)
- Antonia Kowalewski (ORCID: https://orcid.org/0000-0002-9377-7841)
- Léa Berland (ORCID: https://orcid.org/0009-0004-3304-3506)
- Mariateresa Fulciniti (ORCID: https://orcid.org/0000-0002-1432-9742)
- Pegah Taklifi
- Mohammad Rashidian
- Ali Nili (ORCID: https://orcid.org/0000-0002-1286-1858)
- Adam S. Sperling (ORCID: https://orcid.org/0000-0002-9369-4413)
- Taha Rakhshandehroo
- Kathryn Regan (ORCID: https://orcid.org/0000-0002-7604-8305)
- Shreya R. Mantri (ORCID: https://orcid.org/0000-0002-1234-6856)
- Heydar Moravej
- Zeina Gabr
- Zoe Farkash
- Leila Munaretto
- Benjamin B. V. Louis
- Radia M. M. Khan
- Uk-Jae Lee
- Omar Nadeem
- Nikhil C Munshi
- Caron A Jacobson
- Victoria Marie Rivet
- Michael Hemann
Institutions
- Boston University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Parker Institute for Cancer Immunotherapy (US)
- Dana-Farber Cancer Institute (US)
- Center for Cancer Research (US)
- Massachusetts Institute of Technology (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013665
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute